Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,612.00
Bid: 1,613.00
Ask: 1,614.00
Change: 12.00 (0.75%)
Spread: 1.00 (0.062%)
Open: 1,608.00
High: 1,619.00
Low: 1,604.50
Prev. Close: 1,600.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Bird flu testing shows more dairy products are safe, US FDA says

Wed, 01st May 2024 19:39

CHICAGO, May 1 (Reuters) - Preliminary results of tests on additional dairy products show that pasteurization inactivates the bird flu virus, the U.S. Food and Drug Administration said on Wednesday.

The FDA released further test results on foods including sour cream and cottage cheese, after reporting last week that preliminary results from testing showed pasteurization kills the H5N1 virus in milk and baby formula.

The U.S. Department of Agriculture (USDA) has confirmed bird flu in 36 dairy herds in nine states since the first-ever detection in late March, though scientists have said the outbreak is likely more widespread based on findings of H5N1 particles in about 20% of milk samples. One Texas dairy worker tested positive for the virus.

The USDA believes the virus is spreading among cattle primarily through contact with raw milk, Rosemary Sifford, the agency's chief veterinary officer, said on a call that also included officials from the FDA and U.S. Centers for Disease Control and Prevention (CDC). Cows shed the virus at high concentrations in milk, the USDA said.

The FDA so far has tested 297 total retail samples of pasteurized dairy products, and the results released on Wednesday represent tests on 201 of those samples.

"It is a pretty good body of results," Donald Prater, acting director of the FDA's Center for Food Safety and Applied Nutrition, said on the call. "There are probably a few more products that we would look at just so that we make sure that we've got a good national sample."

Scientists are on alert for changes in H5N1 that could signal the virus is adapting to spread easily among humans. The virus has caused serious or fatal infections among people in close contact with wild birds or poultry. It has long been on the list of viruses with pandemic potential, and any expansion to a new mammal species is concerning.

CDC official Dr. Demetre Daskalakis said the agency has monitored about 100 people who have been exposed to bird flu, and around 25 people who developed symptoms have been tested. So far, no additional positive cases have been found.

The agency tested a sample of the virus taken from the farm worker who was infected with H5N1 and found that all commercially available antiviral flu treatments are effective against it. The worker's only symptom was conjunctivitis, commonly known as pink eye.

Currently approved antiviral drugs include Roche's Xofluza and Tamiflu as well as a generic version of Tamiflu, GSK's Relenza and BioCryst Pharmaceuticals' Rapivab.

The CDC said it is working to grow virus from the infected farm worker for additional lab experiments to assess the severity of the illness and transmissibility of the virus.

It said disease monitoring shows no unusual flu activity in people.

The USDA is testing retail samples of ground beef but said results are not yet available. The department has said it is confident the meat supply is safe.

Wild birds that carry the virus appear to be the initial source of infections in dairy cows, according to USDA. Movement of cattle then spread the disease to other herds and subsequently into poultry flocks, the agency said. (Reporting by Julie Steenhuysen and Tom Polansek; Writing by Caroline Humer; Editing by Bill Berkrot)

More News
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.